1. Home
  2. FURY vs CNTB Comparison

FURY vs CNTB Comparison

Compare FURY & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fury Gold Mines Limited

FURY

Fury Gold Mines Limited

HOLD

Current Price

$0.67

Market Cap

115.0M

ML Signal

HOLD

Logo Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

HOLD

Current Price

$2.36

Market Cap

135.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FURY
CNTB
Founded
2008
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.0M
135.7M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
FURY
CNTB
Price
$0.67
$2.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$1.70
$8.67
AVG Volume (30 Days)
212.2K
345.5K
Earning Date
08-11-2026
08-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$64,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$1.23
52 Week High
$1.02
$3.82

Technical Indicators

Market Signals
Indicator
FURY
CNTB
Relative Strength Index (RSI) 70.33 51.02
Support Level $0.66 $2.30
Resistance Level $0.72 $2.69
Average True Range (ATR) 0.03 0.16
MACD 0.01 0.01
Stochastic Oscillator 96.79 45.00

Price Performance

Historical Comparison
FURY
CNTB

About FURY Fury Gold Mines Limited

Fury Gold Mines Ltd is a Canadian-focused high-grade gold exploration company. The company's projects are strategically positioned in two prolific mining regions: the Eeyou Istchee James Bay Region of Quebec and the Kitikmeot Region in Nunavut. Fury Gold's project portfolio comprises the Committee Bay gold project in Nunavut, and the Eau Claire gold, Sakami gold, Elmer East gold and lithium, and Eleonore South gold projects in Quebec. Additionally, it also owns interests in the Kipawa rare earths project and has full ownership of the Zeus heavy rare earths project, both located in the Temiscamingue region of Quebec. The company operates in two reportable segments: Quebec and Nunavut.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Share on Social Networks: